AGC Biologics has partnered with AAVantgarde Bio to manufacture its dual-vector AAV gene therapies targeting inherited retinal disorders. Leveraging the BravoAAV platform, the collaboration aims to advance complex treatments designed to restore vision in patients with genetic blindness.
Macular Degeneration | 24/11/2025 | By Dineshwori
Gerresheimer to Showcase its Silicone Oil-Free Syringe Systems at CPHI Worldwide 2024
The new syringe systems underline Gerresheimer’s expertise as a system and solution provider for highly sensitive innovative drugs.
Macular Degeneration | 03/09/2024 | By Aishwarya | 528
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy